Global health crisis: New therapies emerge to combat antibiotic resistance

Antimicrobial resistance (AMR) has emerged as a critical global health emergency. Data from The Lancet indicates that in 2019, approximately 1.27 million deaths were directly attributable to bacterial resistance, with nearly 5 million associated deaths. Projections from the Global Burden of Disease suggest that by 2050, direct deaths could rise to 1.91 million annually.

Bacteria develop resistance through evolutionary processes, including mutations and horizontal gene transfer. This allows them to inactivate drugs, modify targets, or actively expel antibiotics. A notable example is Escherichia coli, which can transform from a beneficial commensal bacterium into a dangerous pathogen through limited genetic changes.

To combat the rise of superbugs, medical science is exploring alternatives to traditional antibiotics. These include engineered bacteriophages—viruses that can be programmed to target specific bacteria with high precision—CRISPR systems, antimicrobial peptides, and the use of artificial intelligence to design new molecules. These innovations aim to protect the beneficial microbiome while neutralizing resistant pathogens.